Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia-Reference-Cited by-同舟云学术

Matching-Adjusted Indirect Comparison of Blinatumomab vs. Inotuzumab Ozogamicin for Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia

Published:2019-02-13 Issue:4 Volume:36 Page:950-961
ISSN:0741-238X
Container-title:Advances in Therapy
language:en
Short-container-title:Adv Ther

Author:

Song Jinlin,Ma Qiufei,Gao Wei,Cong Ze,Xie Jipan,Zimmerman Zachary,Belton Laura,Franklin Janet,Palmer Stephen

Funder

Amgen

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12325-019-0873-7.pdf

Reference27 articles.

1. Jabbour EJ, Stefan Faderl, and Hagop M. Kantarjian. Adult acute lymphoblastic leukemia. Mayo Clinic Proce. 2005;80(11):1517–27.

2. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017;7:e577.

3. European Medicines Agency. Public summary of opinion on orphan designation: Blinatumomab for the treatment of acute lymphoblastic leukemia. 2017. http://www.ema.europa.eu/docs/en_GB/document_library/Orphan_designation/2009/10/WC500005882.pdf . Accessed 19 Sep 2017.

4. Larson RA, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995;85(8):2025–37.

5. Linker C, Damon L, Ries C, Navarro W. Intensified and shortened cyclical chemotherapy for adult acute lymphoblastic leukemia. J Clin Oncol. 2002;20(10):2464–71.

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world use of inotuzumab ozogamicin is associated with lower health care costs than blinatumomab in patients with acute lymphoblastic leukemia in the first relapsed/refractory setting;Journal of Comparative Effectiveness Research;2024-02

2. Successful treatment with blinatumomab for acute lymphoblastic leukemia in an older adult patient complicated with hepatocarcinoma;Leukemia Research Reports;2024

3. A Comparison of Relative-Efficacy Estimate(S) Derived From Both Matching-Adjusted Indirect Comparisons and Standard Anchored Indirect Treatment Comparisons: A Review of Matching-Adjusted Indirect Comparisons;Value in Health;2023-11

4. Tisagenlecleucel vs. historical standard of care in children and young adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia;Leukemia;2023-10-25

5. Matching-Adjusted Indirect Comparisons of Brexucabtagene Autoleucel with Alternative Standard Therapies for Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Adult Patients;Advances in Therapy;2023-10-06